Assessing thrombocytopenia in the intensive care unit: The past, present, and future

Hematology

Volumn 2017, Issue 1, 2017, Pages 660-666

  Zarychanski, Ryan ^a,b   Houston, Donald S ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT; HISTONE; THROMBIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLEEDING; CANCER PROGNOSIS; CLINICAL OUTCOME; COMPLEMENT ACTIVATION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE COURSE; ERYTHROPHAGOCYTOSIS; HUMAN; INTENSIVE CARE UNIT; OUTCOME ASSESSMENT; SEPSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; BLOOD; INTENSIVE CARE; PROCEDURES;

CRITICAL CARE; HUMANS; INTENSIVE CARE UNITS; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 85038440280     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2017.1.660     Document Type: Article

References (44)

1. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: A systematic review. Chest. 2011;139(2):271-278.
2. Williamson DR, Lesur O, Tétrault JP, Nault V, Pilon D. Thrombocytopenia in the critically ill: Prevalence, incidence, risk factors, and clinical outcomes. Can J Anaesth. 2013;60(7):641-651.
3. Williamson DR, Albert M, Heels-Ansdell D, et al; PROTECT collaborators, the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: Frequency, risk factors, and outcomes. Chest. 2013;144(4):1207-1215.
4. Lauzier F, Arnold DM, Rabbat C, et al. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med. 2013;39(12):2135-2143.
5. Cook D, Meade M, Guyatt G, et al; PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14): 1305-1314.
6. Thachil J, Warkentin TE. How do we approach thrombocytopenia in critically ill patients?. Br J Haematol. 2017;177(1):27-38.
7. Nijsten MW, ten Duis HJ, Zijlstra JG, et al. Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med. 2000;28(12):3843-3846.
8. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 2002; 30(8):1765-1771.
9. Thachil J. Disseminated intravascular coagulation: A practical approach. Anesthesiology. 2016;125(1):230-236.
10. Rice L. HITs and misses of 100 years of heparin. Hematology Am Soc Hematol Educ Program. 2017;2017:667-673.
11. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2015;41(1):49-60.
12. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007;356(9):904-910.
13. Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2015;2015:177-182.
14. Nikiforow S, Berliner N. The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015;2015:183-189.
15. François B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: Role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103(2): 114-120.
16. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011;118(13):3708-3714.
17. Alhamdi Y, Abrams ST, Lane S, Wang G, Toh CH. Histone-associated thrombocytopenia in patients who are critically ill. JAMA. 2016;315(8): 817-819.
18. Nguyen TC, Cruz MA, Carcillo JA. Thrombocytopenia-associated multiple organ failure and acute kidney injury. Crit Care Clin. 2015; 31(4):661-674.
19. Ojha A, Nandi D, Batra H, et al. Platelet activation determines the severity of thrombocytopenia in dengue infection. Sci Rep. 2017;7:41697.
20. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(21):2063.
21. Greinacher A, Selleng S. How I evaluate and treat thrombocytopenia in the intensive care unit patient. Blood. 2016;128(26):3032-3042.
22. Claushuis TA, van Vught LA, Scicluna BP, et al; Molecular Diagnosis and Risk Stratification of Sepsis Consortium. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood. 2016;127(24):3062-3072.
23. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149: 38-44.
24. Zarychanski R, Abou-SettaAM, Kanji S, et al; Canadian Critical Care Trials Group. The efficacy and safety of heparin in patients with sepsis: A systematic review and metaanalysis. Crit Care Med. 2015;43(3):511-518.
25. Clinicaltrials.gov. Heparin Anticoagulation to Improve Outcomes in Septic Shock.Available at: Https://clinicaltrials.gov/ct2/show/NCT01648036. Accessed 4 August 2017. 2017.
26. La Rosee P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015;2015:190-196.
27. Alejandria MM, Lansang MA, Dans LF, Mantaring JB III. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013; (9):CD001090.
28. Rimmer E, Houston BL, Kumar A, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: A systematic review and meta-analysis. Crit Care. 2014;18(6):699.
29. Menard CE, Kumar A, Rimmer E, et al. Evolution & impact of thrombocytopenia in septic shock. Intensive Care Med Exp. 2016; 4(Suppl 1):A586.
30. Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med. 2015; 373(7):642-655.
31. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1336.
32. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebocontrolled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89(9):3118-3128.
33. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486-552.
34. Abrams D, Baldwin MR, Champion M, et al. Thrombocytopenia and extracorporeal membrane oxygenation in adults with acute respiratory failure: A cohort study. Intensive Care Med. 2016;42(5):844-852.
35. Ning S, Barty R, Liu Y, Heddle NM, Rochwerg B, Arnold DM. Platelet transfusion practices in the ICU: Data from a large transfusion registry. Chest. 2016;150(3):516-523.
36. Aubron C, Flint AW, Bailey M, et al. Is platelet transfusion associated with hospital-acquired infections in critically ill patients?. Crit Care. 2017;21(1):2.
37. Tariket S, Sut C, Hamzeh-Cognasse H, et al. Transfusion-related acute lung injury: Transfusion, platelets and biological response modifiers. Expert Rev Hematol. 2016;9(5):497-508.
38. Kaufman RM, Djulbegovic B, Gernsheimer T, et al; AABB. Platelet transfusion: A clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205-213.
39. Hallet J, Lauzier F, Mailloux O, et al. The use of higher platelet: RBC transfusion ratio in the acute phase of trauma resuscitation: A systematic review. Crit Care Med. 2013;41(12):2800-2811.
40. Bawazeer M, Ahmed N, Izadi H, McFarlan A, Nathens A, Pavenski K. Compliance with a massive transfusion protocol (MTP) impacts patient outcome. Injury. 2015;46(1):21-28.
41. Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth SJ, Arnold DM. Platelet transfusions for critically ill patients with thrombocytopenia. Blood. 2014;123(8):1146-1151, quiz 1280.
42. Estcourt LJ, Birchall J, Allard S, et al; British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365-394.
43. Haas B, Chittams JL, Trerotola SO. Large-bore tunneled central venous catheter insertion in patients with coagulopathy. J Vasc Interv Radiol. 2010;21(2):212-217.
44. Zeidler K, Arn K, Senn O, Schanz U, Stussi G. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion. 2011;51(11):2269-2276.